Abstract

Angiogenesis, the formation of new blood vessels from pre-existing ones, is a critical process in tumor growth and metastasis. Solid tumors rely on angiogenesis to secure the necessary nutrients and oxygen for sustained growth and to facilitate the spread of cancer cells. Targeting angiogenesis has emerged as a promising therapeutic strategy in cancer treatment, particularly through the inhibition of vascular endothelial growth factor (VEGF) signaling pathways. This article reviews current therapeutic approaches to targeting angiogenesis in solid tumors, including monoclonal antibodies, small molecule inhibitors, and emerging strategies such as immunotherapy and combination treatments. We also discuss the challenges of resistance and the role of biomarkers in predicting treatment efficacy. By exploring these therapeutic avenues, we aim to highlight the potential of anti-angiogenic strategies in improving patient outcomes in solid tumors.